Healthcare
Live Price
Offline$0.1471
+15.69% today
1Y Change
-41.30%
Window
Jun 30, 2025 → Jun 25, 2026
Coverage: 252 bars · Jun 30, 2025 → Jun 25, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Paradigm Biopharmaceuticals Limited (PBIGF) is a Healthcare stock with a market cap of $70.00M and listed on OTC. The stock last traded around $0.15 and down 41.3% across the available one-year price window (Jun 30, 2025 → Jun 25, 2026). Baseline metrics include revenue growth of -20.8%, EPS growth of +70.2%, a dividend yield of 0.0%. What stands out right now is revenue -20.8%, EPS +70.2%, free cash flow +75.7% with operating margin -63782.8% and ROIC -493.0%. Valuation already assumes a fairly strong business story at price/sales 1193.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PBIGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
PBIGF is 60.14 pts behind over the shared 1Y window.
PBIGF had 60.76 pts deeper max drawdown than SPY.
PBIGF beat SPY in 0 of 2 calendar years shown and trailed in 2.
PBIGF
-41.30%
Normalized return
SPY
+18.85%
S&P 500
Excess Return
-60.14 pts
Relative to SPY
PBIGF Max Drawdown
-69.90%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for PBIGF and SPY.
| Year | PBIGF | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -45.45% | +6.71% | -52.16 pts | SPY |
| 2025 | +3.88% | +11.19% | -7.32 pts | SPY |
Unable to load analyst forecasts.
Timed out loading forecasts for PBIGF
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.